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This  Working  Paper  has  been  prepared  as  support  for  the  European  Commission’s 
Communication  to  the  European  Parliament,  the  Council  and  the  Economic  and  Social 
Committee. 
A detailed overview of the progress made in implementing the action plan set out in the 
Strategy is provided in the Annex 1. 
Actions are subdivided into four headings as follows: 
1)  Harvesting the potential (Actions 1-12):  
Actions under this heading aims at developing skills, supporting European research, 
providing  a  strong  European  intellectual  property  system,  facilitating  access  to 
capital, networking all the various stakeholders working in biotechnology in Europe 
and increasing the proactive role of the public authorities.  
2)  A key element for responsible policy: governing life sciences and biotechnology 
(Actions 13-23):  
These actions includes dialogue among stakeholders, ethical and social implications, 
consumers’ right to choose and the legislative framework.  
3)  Europe in the world – responding to global challenges (Actions 24-28):  
These  actions  highlight  Europe’s  role  in  developing  international  guidelines  and 
indicate the areas where Europe can support the developing world in its efforts.  
4)  Implementation  and  coherence  across  policies,  sectors  and  stakeholders 
(Actions 29 and 30):  
This final group of actions focuses on the role of the Commission in evaluating and 
further developing the Europe’s biotechnology policy in the coming years. 
In the current early phase of implementation of the action plan, this overview focuses on 
action  undertaken  by  the  Commission,  and  only  provides  occasional  reference  to  other 
stakeholder activities. 
The full text of the first report of the Competitiveness in Biotechnology Advisory Group 
with Industry and Academia (CBAG), appointed by the Commission in accordance with 
Action 10b of the Action Plan, is provided in Annex 2.  
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ANNEX 1  
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 N°  Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
1  The Commission will, together with Member States,
        identify the education needs in life sciences
within the 'Ten-year objectives for learning in the
knowledge society' and strengthen a broad
education and understanding of life sciences, and
develop and train a skilled workforce in life
sciences by issuing recommendations for curricula
and teacher training. Community support can be
provided under the Comenius and Erasmus
programs.
           A call for proposals under the second phase of 
the Leonardo Program (for vocational training) was 
launched (2005-2006). The different measures of this 
programme allow for project development in this field.
           A detailed work program on the future 
objectives of education and training systems was 
adopted on 14.2.2002. Work had already started on 3 
priority objectives: 'basic skills', ICT and 'Math, 
Sciences and Technologies'
        While the Commission support this action through 
its various education programs, recommendations 
for developments of curricula are strictly 
competence of Member States. Most Member 
States have instituted measures to revamp science 
education, with an emphasis on new technology.
Members States, 
Commission, 
private sector
  promote continuing education and refresh the
current competence of the scientific workforce, as
set out in its communication on the European area
of lifelong learning. Community support can be
provided under the Leonardo program  
           The Communication on 'Making a European 
Area of Lifelong Learning a Reality' includes key 
concrete actions to provide people of all ages with 
equal and open access to high-quality learning 
opportunities. An interim report on progress towards 
implementing the lifelong framework was presented by 
to the 2003 Spring European Council.
           In several Member States (F, UK, DK, IRL, 
German länder) the needs and options for continuing 
education are mapped and strengthened.
  support discussion for specialist scientists, with
the objective of stimulating an exchange across
disciplines. Community support can be provided
under the Erasmus program
           A number of  'Thematic Network Projects' in the 
specific area of Biotechnology consisting of university 
cooperation projects have been supported under the 
Socrates-Erasmus program (for education)
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
Investing in people 
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 N°  Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
2 (a)             the Commission will explore with Member 
States the opportunity and best way to establish 
efficient methods to match a skilled workforce 
with job opportunities, involving effective 
communication of open positions, collaboration with 
established companies and a labour force aware of 
available employment options.
              high level task force was established in 2001 to 
address the challenges of skills and mobility on 
European labour markets.  
           On the basis of the task force's report,       in 
February 2002 the Commission adopted an Action 
Plan for Skills and Mobility, endorsed by the 
Barcelona Summit in March 2002. 24 separate actions 
were identified with many linked directly to investing in 
people and ensuring skills matching. Action 2 seeks to 
promote  maths, science and technology skills, action 
4 seeks closer links between education, industry and 
careers guidance. Actions 23 and 24 explicitly address 
the issue of a one stop mobility and 
information/qualifications website and the existing 
EURES website on the classification of professions.
           The Commission works together with Member 
States via the European Employment Strategy to 
improve and enhance employment, seeking both more 
and better jobs. As part of this process, Member States 
prepare and present National Action Plans (NAPs) for 
employment on the basis of guidelines agreed at the 
beginning of the year. Within the guidelines for 2002, 
and thus in all NAPs, is action on matching jobs with 
skills and combating bottlenecks.Some Member States 
try to facilitate career movements between academia 
and the private sector.
Member States, 
Commission
2 (b)    The Commission will explore with Member States 
possible measures to attract and retain scientists 
and avoid brain drain. 
              In the framework of the Mobility Strategy for the 
European Research Area, (COM(2001)331)
►“The Researcher’s Mobility Portal” 
(http://europa.eu.int/eracareers) was launched in 
summer of 2003. 
► Dedicated national Mobility Centres have become 
in part operational in 2003, and 
► the European network of Mobility Centres will 
formally be launched in the spring of 2004.
        In the communication "Researchers in the 
European Research Area: one profession, multiple 
careers" (COM(2003)436) the Commission is 
addressing for the first time at European level, the 
issue of the researcher profession and researchers 
careers. 
           A specific "Life Sciences Mobility Consultance" 
aiming to help researchers in the life sciences to find 
funding opportunities, training programmes and 
vacancies, will be linked to the Researchers  Mobility 
Portal.  
        the “European Researcher’s Charter", a 
framework for the career management for human 
resources in R&D, based on voluntary regulation and a 
“Code of Conduct for the recruitement of 
researchers” based on best practise, to improve 
recruitment methods will be launched in the course of 
2004.
Member States, 
Commission
2003
onwards
2003
onwards
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Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
           in order to make Europe more attractive for 
researchers, a Commission proposal for a Directive 
and an Action Plan on the entry and stay of third 
country researchers within the EU was adopted on 
16 March 2004 (COM(2004) 178)
           Under the specific program "Structuring the 
European Research Area", the Commission  offers 
increased opportunities for mobility across Europe and 
implement actions to counteract the brain drain.  As a 
result of the first calls for Marie Curie-actions under 
the Human Resources and Mobility programme 47 life 
sciences and biotechnology related actions 
(including 10 training networks, 12 excellence grants, 6 
inter European fellowships, 4 reintegration and 8 
international fellowships, 3 technology transfer 
fellowships that allow companies to host fellows,  4 
conferences and training courses) have  been selected 
for funding to a total amount of just under € 47 million 
(representing 13% of a total indicative budget of € 356 
million for Marie Curie actions for the first calls)
             studies to assess and benchmark the multiple 
career paths of researchers will be launched in 2004.
         New calls for Marie Curie actions will be launched 
in 2004-2005
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
3 
2002-06 
  The Commission will enhance support for life 
sciences and biotechnology research, technological 
development, demonstration and training activities 
under the Sixth Framework Program 2002-2006 
aimed at 
                contributing towards the creation of the 
European Research Area.
                   supporting Biotechnology research under 
5 thematic priorities
                   to facilitate the objectives of Europe-wide 
collaborations, attaining critical mass and 
simplification of administrative procedures.
            The results of the first calls for proposals under 
the Sixth Framework Program( FP6) have among 
others  resulted in  the funding of :
 ► 103 research projects with an initial EC 
contribution of €604 million under  the Thematic 
Priority 1 " Life Sciences, Genomics and Biotechnology 
for health ", The projects, involvinvolving  more than 
2020 laboratories including 274 SME’s. The second  
call for proposals deadline 13 November 2003 has an 
indicative budget of €415 million,
►  36 research projects  awarded an initial EU 
contribution of € 206 million in the Thematic Priority 5"  
Food Quality and Safety". The projects  involving some 
685 laboratories including 103 SME’s. A second call 
for proposals have been published 5 November 2003 -
deadline 5 February 2004- indicative budget 192 
million Euro. These research projects will be 
complemented with 11  actions  (EU contribution of 
€ 8.1 million) supporting   the programme cooperation 
and the coordination of research activities  carried out 
at national or regional level in the areas of health and 
food research.
         New calls for proposals  will be published in 
2004 and 2005 for the various Thematic Priorities 
including Thematic Priority 1 and 5.   
          A European technology platform on plant 
genomics and biotechnology  is currently being set 
up with the aim to develop an EU wide strategy to re-
build and strengthen the S&T base in plant genomics 
and biotechnology , taking into account the needs of 
the different industrial sectors (food, chemicals, 
pharmaceutical  etc). It is expected to be officially 
launched in spring 2004.
Members States, 
EIF, Commission
Research
2002-06
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Further follow-up
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
   encouraging SME participation, 
international cooperation and mobility and 
training of researchers. 
           As a result of the first call for proposals about 13% 
of the budget will be allocated to SMEs under the 
thematic priorities and 52 Specific SME activities (Co-
operative and collective research) and research and 
innovation activities (Economic and Technological 
Intelligence actions) will be implemented to support a 
large community of SME’s to develop innovation in 
healthcare, food quality and safety, agriculture and 
aquaculture.
           Nearly 20 Specific support actions will be 
implemented to facilitate co-operative research and 
innovation partnership in life sciences and 
biotechnology with INCO target countries (including 
Developing countries, Mediterranean partners, 
Western Balkans, Russia and NIS).
           New calls for specific activities promoting the 
participation of SME's , international collaboration  and 
coordination of national activities  will be launched in 
2004 and 2005,
  The Commission and the Member States and in 
collaboration with the European Investment Fund 
(EIF), will develop a competitive bioinformatics 
infrastructure in support of biotechnology research 
and focus support for the development of research 
in computational biology and bio-medical 
informatics. 
           Several projects supporting bioinformatics are 
funded under FP5, the largest being TEMBLOR, a 3-
year project with an EU contribution of €19,4m to 25 
participants, coordinated by the European 
Bioinformatics Institute (EMBL-EBI)
        The Commission and the EIB/EIF have established 
a working group to investigate the issue of the 
financing of infrastructure, including bioinformatic 
infrastructures (see action 6a). The work of this group 
is continuing.
           The European Strategy Forum on Research 
Infrastructures (ESFRI), set up by Member States in 
2002, concluded in its firts annual report published in 
September 2003 that the body should extend its 
activities and address specific needs for scientific 
areas such as life sciences.
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
           Under the specific program "Structuring the 
European Research Area"(2002-2006) specific support 
is provided to research infrastructures. Four  projects 
(EU contribution of 48,7 M€), currently under 
negotiation, will provide access for the European 
research community to synchrotron  radiation sources 
and free electron lasers; to museum collections of 
micro-organisms, fungi, plants, animals and fossils, to 
mouse strains including transgenic strains; to network 
of European seed banks.  
           The first call for proposals in the area of functional 
genomics under Thematic priority 1 resulted in the 
funding of" A European Network for Integrated 
Genome Annotation"
           The 4th call for research infrastructures under 
the specific programme " Structuring the European 
Research area" ( deadline 4 March 2004) includes 
constructions of new infrastructures, feasibility studies 
and technical preparatory work for new infrastructures 
and actions to promote a more co-ordinated approach 
to research infrastructures in Europe. 
           The second  call ( deadline 13 November 2003) 
in the area of functional genomics under Thematic 
priority 1 invited proposals for Bioinformatics grid for 
European genomics research and development of an 
integrated software platform to tackle genomic 
sequence-structure-function relationship.
 
(1) COM(2002) 27 of 23 January 2002 
  1. Harvesting the potential  
  10      
 N°  Action  / 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
4  To enhance the supply of specific management and 
legal skills:
           Member States and national biotechnology 
associations should examine the opportunity of 
creating self-sustained networks of biotechnology 
company managers at the national level.
           Member States and the Commission should 
promote collaboration between law schools, law firms 
and companies for the development of specific 
legal competence needed by biotechnology 
companies.
           In 2004 the Commission, together with Member 
States and national industry associations, will explore  
the opportunities and best ways of providing this 
expertise at national level .
        Young biotechnology companies often need better 
access to entrepreneurial/management skills and 
specific legal expertise (e.g. IPR/licensing contracts). 
Creation of self-sustained networks of biotechnology 
company managers, possibly including the involvement 
of specialized law schools/firms for the development of 
specific legal competence, might help to improve 
access to expertise. Such networks have been created 
in several Member States (A, S, F, I,).
Member States, 
academia, 
professional 
associations, 
Commission
Management and legal services
2003
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE 
State of implementation of action plan
 (1) 
 N°  Action  
/ Timeframe 
Description of the Action  State of play  Comments/ 
Further follow-up 
Implementer 
5 (a) To finalize a strong, harmonized and affordable 
European intellectual property protection system by
           Member States urgently transposing into 
national laws the Directive 98/44/EC on the Legal 
Protection of Biotechnological Inventions.
           To date, seven Member States have transposed 
the Directive (DK, FIN, IRL, UK, GR, ES, PT).
           The Commission has launched the third stage of 
formal infringement proceedings against Members 
States which have not yet  transposed the Directive. In 
the light of the recent ruling of the Court of Justice 
confirming the compatibility of the Directive with various 
legal principles and internation obligations, the 
Commission has decided to sue an action before the 
ECJ against Member States which have not transposed 
the Directive into their national law.
           As provided for by Article 16(b) of Directive 
98/44/EC, on 14 January 2002, the Commission has 
adopted a report assessing of the implications for 
basic genetic engineering research of failure to 
publish, or late publication of, papers on subjects 
which could be patentable as required under Article 
16(b) of Directive 98/44/EC on the legal protection of 
biotechnological inventions (COM(2002)2 Final).
           As provided for by Article 16(c) of Directive 
98/44/EC,  the Commission is currently preparing its 
second annual report on the development and 
implications of patent law in the field of biotechnology 
and genetic engineering (the first annual report was 
adopted in 2002 - COM(2002) 545).
Member States, 
Council, 
Commission
           The Commission has already set up a group of 
experts in economics, law and natural sciences to 
examine controversial issues linked to biotechnology 
patent and to help it to prepare future annual reports. 
Two topics were studied in March and May 2003 
respectively i) the scope to be given to patents related 
to sequences or partial sequences of genes isolated 
form the human body, and ii) the potential patenting 
of human stem cells and cell lines obtained from 
them. Minutes from those discussion and reports 
prepared by experts will be made available at the same 
time as the Commission second annual monitoring  
report.
Exploitation of intellectual property
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
5 (b)            Council adopting the Community Patent 
Regulation. 
           On 1.8.2000 the Commission adopted a Proposal 
for a Council Regulation on Community Patent 
(COM(2000) 412 Final). 
           The European Parliament delivered its opinion on 
10.4.2002. 
           The Council reached a political agreement on 
3.3.2003.
           The political agreement reached on 3 March 2003 
enables the work on the details of the Regulation to 
continue efficiently in the Council with a view to its 
adoption as soon as possible. 
Member States, 
Council, 
Commission
5 (c)         Member States and the Commission clarifying
rules on ownership of intellectual property
stemming from public research and monitoring the
effect of implementation of patent legislation on
research and innovation.
           A Commission study that provides a detailed 
comparative analysis of the Intellectual Property 
Research (IPR) rules applicable to publicly-funded 
research, their evolution and their effects, in the 15 EU 
Member States,as well as in the US and Japan, has 
been finalised and will be published soon. The study is 
currently being analysed in view of proposing 
recommendations or guidelines which could improve the 
coherence of the IPR regimes applicable to publicly 
funded research in the European Union
        An expert group of technology transfer and legal 
specialists has produced “Management of Intellectual 
Property in Publicly-funded Research Organisations : 
towards European guidelines”, 
http://europa.eu.int/comm/research/era/pdf/iprmanagem
entguidelines-report.pdf
           This action will in particular benefit the 
biotechnology sector, since the majority of technology 
transfer activity and licensing from the public research 
sector is in this area. The analysis of the study and 
expert group recommendations will allow to identify 
problems and good practices, and to define possible 
actions by the Commission and/or Member States 
aimed at improving the efficiency and coherence of 
these rules in the EU, taking into account the 
international context.
        Through the method of open coordination, wider IPR 
issues will be discussed with Member States as part of 
the "3% action plan" (COM(2002)499)
Member States, 
Council, 
Commission
2002
onwards
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
5 (d)            encouraging awareness training in the strategic 
use of IPR during the entire research and innovation 
process and raising awareness among academics of 
the commercial potential of their research, 
encouraging entrepreneurship and movement 
between academia and companies.
Various initiatives have recently been launched at 
regional, national and Commission level, such as 
           the PROTON network of technology transfer 
licensing offices in Europe aimed at increasing 
professionalism of technology transfer activities in 
Europe.
           A workshop to explore the establishment of a EU 
network of managers of public intellectual property 
resources in agriculture took place in January 2004. 
            A project analysing IP management within and 
consortium agreements of FP5 biotech research 
projects will,by the end of 2004, produce guidelines and 
best practise for IP management in collaborative 
research projects.  
Member States, 
Council, 
Commission
        the IPR-Helpdesk which provides a helpdesk on IP 
issues for mainly for participants of the EU RTD 
framework program  or the “EuroBioBizz” training 
activity that helps potential biotech entrepreneurs in 
writing professional business plans . 
           On a broader level, the Gate2Growth Initiative 
provides tools and networks for access to finance and 
better exploitation of knowledge.
           The websites of the newly established IPR-
Helpdesk and Gate2Growth Initiatives may serve as 
an information platform for communicating the various 
national and regional initiatives and providing 
information on and links to training and awareness 
activities. 
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
5 (e)            taking steps to promote international dialogue 
and co-operation with a view to work towards a 
level playing field with industrialized countries in 
patent protection on biotechnology inventions, 
ensuring an effective level of protection for 
innovation in this field.
           Harmonization of intellectual property law in 
industrialized countries is currently being discussed at 
the level of the World International Property 
Organization (WIPO) in its Standing Committee on 
Patent Law (SCP). A number of very important issues 
are being discussed, such as the patentability criteria, 
the  patentable subject matter and the grace period.
           The Commission prepared a working document 
on these issues which was discussed with the Member 
States during the General Assemblies of WIPO (23 
September-1 October 2002) which decided that works 
dedicated to the PCT reform should be pursued.
           Discussion on Substantive Patent Law Treaty 
(SPLT) will continue under the auspices of WIPO 
Member States, 
Council, 
Commission
           In parallel, the reform of the Patent Cooperation 
Treaty (PTC) has been undertaken in order to 
streamline and to simplify the PCT procedure and to 
avoid duplication of works. The real purpose of this 
exercise is to solve the increasing workload of the 
Patent Offices.
Both exercises should allow to create a more user 
friendly system for the applicants and to reduce the 
discrepancies on patent law among the Parties of WIPO
            The "grace period" is a particular important 
issue regarding research co-operation on an 
international level. For this reason, the Commission has 
organized two workshops on this topic
           The “grace period” discussed during the 
workshops could serve as a basis for defining a 
common European standpoint at the current SPLT 
negotiations
2002
onwards
 
(1) COM(2002) 27 of 23 January 2002 
  1. Harvesting the potential  
  15      
 N°  Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
6 (a)  The Commission should, together with the European 
Investment Bank (EIB) and the European Investment 
Fund (EIF), strengthen the capital base for the 
biotechnology industry, by:
           seeking to stimulate investments in research and 
technological innovation via complementary financing 
on the basis of the co-operation agreement signed in 
June 2001 between the Commission and the EIB 
group.
  Three workings groups chaired by the 
Commission, European Investment Bank (EIB) and 
European Investment Fund (EIF) meet on an ad hoc 
basis to investigate the issues of  
           support R&D financing via direct financing and 
guarantee mechanisms; 
           financing of infrastructures; 
        availability of risk capital and support to 
incubators.
        The EIB has increased the capital available to EIF for 
investvents in high tech venture capital by 500 million 
Euro.
        The financing instruments of the EIB, including 
information on recent projects and case studies, will be 
actively promoted by the Commission and EIB, e.g., 
through their websites and through information 
contained in the “INFO PACK” to the new framework 
program. Concrete results and recommendations for 
further collaboration and the development of new 
financing instruments is expected by the launch of Sixth 
Framework Program.  In addition, the Commission will 
target appropriate industrial partners who are currently 
project participants of the framework program to 
evaluate the interest for and potential of complementary 
financing instruments of the EIB. 
EIB group, 
Commission
  Since June 2001, the EIB has made R&D the 
centerpiece of its ongoing "Innovation 2000 Initiative" 
(i2i), one of the two pillars of the co-operation 
agreement between the Commission and EIB with the 
Framework Program for Research and Technological 
Development (FPRTD). EIB has substantially increased 
its financing of research and innovation. From 1990 to 
1999, EIB had loaned 245 million € . From 2000 to 
present, under i2i, EIB approved 9.1 billion € in loans, of 
which 4.2 billion for research.
                   R&D will remain a key objective for EIB lending 
in the years to come. A particular focus will be on 
supporting private R&D by SMEs, large companies as 
well as "mid-caps" and on fine-tuning EIB financial 
instruments to each sector. The EIF will continue to 
support universities and research centers in the creation 
of investment funds and new vehicles. Furthermore, EIF 
is currently setting up a consultancy operation. In doing 
so, EIF aims to bridge the gap between research and 
product development.
Capital base
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
6 (b)            seeking to stimulate investments in business 
incubators through the EIF Start Up Facility
        In the year 2001, the EIF has done major
investments in biotech VC funds linked largely to
regional clusters and bioincubators, such as
“Heidelberg Innovation” in Germany, “BioAm” in 
France and “Symbion” in Denmark. These
commitments have been done through EIB funding,
which represent 90% of the EIF VC resources.
Altogether, 8 funds have been created that devote
100% of their capital to the biotech sector. Through 55
general funds, 223 biotech start-ups have been
financed. Another €49 million were invested in smaller
and regional start-up funds through the ETF start-up
facility. 
           Through the multi-annual action plan (MAP), €317 
million of financing will be available for the ETF start-up 
facility for the 2001-2005 period, with a focus on 
incubators and seed-capital funds. 
  A working group comprising venture capital fund 
managers, banks, industry, bio-cluster managers, 
research organizations and research and industry 
ministries could be established to investigate how other 
regional actors could be involved in public-private 
partnerships, together with the EIF, to improve early 
stage financing for biotech start-ups. 
           Increase of the EIB VC funds will be investigated.
EIB group, 
Commission
6 (c)            studying measures to support technology 
transfer mechanisms, such as financing of patent 
pools or other methods for patent exploitation.
           A specific Biotech and Finance Forum working 
group established in 2003 will continue its work in 2004 
to identify best practices in financing of technology 
transfer related to biotechnology and propose new 
financing instruments for technology transfer (proof of 
concept funds, patent pools etc.). 
           A workshop to explore the establishment of a EU 
network of public intellectual property resources in 
agriculture took place in January 2004. The network 
should provide technology packages and patent pools in 
particular for small European speciality breeders and for 
humanitarian use in developing countries. 
           The US experience has shown that professional 
technology transfer structures are a major success 
factor for the exploitation of publicly funded research 
through licensing and start-up generation. A majority of 
the $1b of royalties earned by US and Canadian public 
research institutions in 2002 have originated from 
inventions in life sciences and biotechnology, mainly 
through license income from SMEs. A similar potential 
in the EU is largely untapped and needs to be exploited 
through national and EU initiatives.
EIB group, 
Commission
2002
onwards
2002
onwards
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6 (d)            studying measures to encourage commercial 
financing of companies based on a medium-term 
investment perspective.
        Recommendations of the Biotech and Finance
Forum working group delivered in 2002 on "Financing of
biotech companies" have been discussed with
institutional investors and the EIB/EIF early 2003. The
EIB has decided to provide an additional 500 million
euros to the EIF to provide further venture capital to
innovative SMEs, which will be particular beneficial for
follow-up investments in biotech companies.
           The EIF will make available an additional €0,5b for 
VC funds focusing on innovative SMEs. The potential 
for joint initiatives of the EIF and Member States should 
be explored.
EIB group, 
Commission
        The Commission finalized the terms of reference for
a “Biotech finance study” that should investigate
financing gaps in the various Member States and other
countries. 
           The Biotech Finance Study will examine in detail, 
on a country-by-country basis, the respective ease of 
access to capital that biotechnology companies have: 
(a) at each stage of finance, (b) take-up/usage of 
EIB/EIF finance, and (c) in general, relative to other 
innovative companies.
2002
onwards
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7            To strengthen the work of the Biotechnology 
and Finance Forum by the inclusion of relevant 
major stakeholders to provide advice into policy 
development in the field of capital supply. 
        The Biotechnology and Finance Forum (BFF)
was set-up as a joint initiative between the European
Commission and the European Association of Security
Dealers in 1997 to promote networking between
researchers, entrepreneurs, industry and finance and
support financing of biotech ventures. The BFF has
organized 6 conferences in recent years, featuring
investment presentations by biotech companies, from
which numerous important financing deals have
emerged. The BFF advisory board includes all relevant
biotech stakeholders in Europe, such as EuropaBio, the
European Federation of Biotechnology (EFB), the
European Venture Capital Organization (EVCA), the
EIB, EIF and Eureka. Representatives of major bio-
clusters, venture capital firms, consultants, etc. in the
biotech sector are also present.
        An BFF working group in 2004 will look into 
financing of professional technology transfer (see action 
6c). 
        The BFF board will meet in early 2004 to review the 
activities and to set priorities for working groups and 
other activities for 2004/2005. 
        A BFF conference activities will continue and seek 
to consolidate with other EU events.
Commission
2002
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8 (a)         The Commission will support creation of a
commercial biotechnology web portal for Europe
that will help free access to information and
networking available Internet platforms. 
        Following the launch of a call for proposals, five
responses have been received and they are currently
being evaluated 
        The web site(s) would be expected to be fully
operational by 2004. 
Commission
8 (b)            the Commission will develop its newly created 
Commission web site to provide a broad entry 
platform into the Commission’s work on 
biotechnology.
           A thematic portal on Europa website under 
‘Biotechnology’ is currently available. 
           Further developments of the structure and contents 
of this site are currently under evaluation. The web site 
is expected to be developed and operational by 2004
Commission
9 (a)            Member States, their regions, the Commission 
and the EIB will support stronger interregional co-
operation, e.g. through a network of biotechnology 
regions. Crossborder and interregional co-operation 
can receive funding from the Interreg programs 
(notably Interreg IIIB and IIIC).
           While the Commission through its regional policy 
supports this action, the procedures of selection of 
concrete projects are matter for the Member States.
           A project have been partially co-financed by the 
European Fund for Regional Development. The project 
will promote the growth of the Scottish Centre for 
Genomic Technology and Informatics (GTI) which is 
dedicated to providing specialist genomic and 
computational resources necessary for the escalating 
number of life sciences and biotechnology researchers 
who utilise microarray (DNA chip) technology. GTI will 
act as a catalyst in the formation of post-genomic based 
SMEs, provide necessary advice and expertise which 
will further stimulate growth in the biotechnology cluster 
industries being generated in the East of Scotland. 
           Stronger interregional co-operation in the life 
sciences and biotechnology area is developing in a 
number of European regions. These activities, such as 
interregional networks, can be considered eligible for 
financing under the INTERREG III initiative. The 
INTERREG III programs (strands A, B and C) are now 
operational in all Member States. In particular, the 
INTERREG III C program launched its first call for 
proposals of projects on 10 October 2002, which closed 
on 10 January 2003. All relevant information about this 
program can be found on the following website: 
www.interreg3c.net
Member States, 
regions, EIB, 
Commission
Networks in Europe
2002-03
2002-03
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9 (b)            Member States, their regions, the Commission 
and the EIB will support networks of biotechnology 
clusters. In addition, the Commission will organize a 
European competition between Biotechnology 
Innovation clusters, to highlight their capability to 
develop a cluster with a focus of excellence in a 
specific scientific field.
        Networks of biotechnology clusters have been and
are being developed in Europe. Examples are the
BioValley network of clusters covering Rhone-Alp
(FR), Freiburg (DE) and Basel (CH), as well as the
Medicon Valley covering both Danish and Swedish
regions around Copenhagen and Lund. 
        The Commission, through the FP6, will support the
SCAN BALT initiative, which aims at networking
biotechnology activities and clusters around the Baltic
Sea. 
           Networking of biotechnology clusters can be 
actively supported within the FP6 through specific 
support actions in the life science thematic priorities as 
well as through measures financed through the specific 
program on “structuring the European Research 
Area”.
A workshop will take place in Zurich in March 2004, 
before the annual BioSquare conference, which will 
bring together managers of biotech clusters to discuss 
the pros and cons of networking of bioregions through 
"virtual clusters" or "meta-regions", identify added value 
of networking and to make policy recommendations for 
incentives at regional, national and EU level.
Member States, 
regions, EIB, 
Commission
10 (a)            the Commission will establish a 
competitiveness monitoring function and a 
contact network with Member States ministries 
with responsibility for competitiveness in 
biotechnology. Monitoring should include impact on 
European competitiveness of legislation and policy 
measures. 
           The contact network has been established with 12 
out of 15 Member States participating. 
        A reflection on the possible reinforcement of the role 
of the contact network will start in 2004.
10 (b)            the Commission will establish a 
Competitiveness in Biotechnology advisory 
group with industry and academia to assist in 
identification of issues affecting European 
competitiveness. The Group will provide input into 
the Commission’s regular reports on Life Sciences 
and Biotechnology.
           The Competitiveness in Biotechnology Advisory 
Group has been appointed by the Commission in 2003. 
It has delivered its first report.
           The first report concentrated on the issues of 
access to finance and regulation (see annex 2 of the 
staff working paper).
A proactive role for public authorities
Member States, 
Commission
2003-06
2002
2002
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11 Transparency in the administrative process:
           The Commission and Member States should aid 
applicants, especially from start-up companies and 
SME’s, requesting approval through the regulatory 
process. 
           the Commission should issue a guide to 
Community regulation for users and for 
entrepreneurs who have limited staff and expertise in 
the regulatory and legal fields.
Such a guide should also benefit non-EU (e.g. 
developing world) applicants and the general public.
           The Commission already provides various but 
spread and selective information on Community 
biotechnology legislation/its management, such as
           the information it provides about the various 
"dossiers" concerning applications for EU authorization 
of GMOs; 
           web-site on pharmaceutical legislation;
           SMEs User Guide on biotechnology
           The main aims of this action are to facilitate 
comprehensive information on biotechnology-relevant 
legislation, and ultimately, long-term investment in 
biotechnology that is in compliance with the developing 
regulatory framework in the EU, and public 
understanding of the development of that framework.
The new Guide will be commissioned in 2004, when 
the new legislative framework will be in place, and will 
be the main instrument for access to information. It will 
be published on the Commission's biotechnology web-
pages and regularly updated.
Member States, 
Commission
12            In collaboration with the involved actors, the  
Commission will benchmark good practices in 
clustering biotech companies and in the work of 
business incubators and disseminate results.
           The Commission will establish with Member 
States a program for benchmarking relevant 
elements of biotechnology policies, in addition to 
existing benchmarking structures.
            a benchmarking program involving interested 
Member States was endorsed by the Council and 
included in the road map adopted on 26 November 
2002.
        the possible contents of the benchmarking program
will be discussed in 2004 within the contact network with
Member States ministries with responsibility for
competitiveness in biotechnology (see action 10a) on
the basis of the roadmap. The supporting study has
been commissioned.
Commission
2003
onwards
2003
onwards
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13 (a)            The Commission will propose a framework for a 
process of dialogue and follow-up with 
stakeholders as a result of the European strategy 
for life sciences and biotechnology. The framework 
will notably include a broadly based Stakeholders’ 
Forum. 
        In December 2003 the Commission organised the
first stakeholder conference with the objective of to
explore the effect of human perception on risk
assessment and risk analysis and its significance and
implications in promoting key scientific paradigms
underlying regulatory oversight and governance. In
particular, the conference addressed the issues of risk
assessment and risk analysis, and how such
processes could be improved.
           The conference, entitled ‘Risk Perception: 
Science, Public Debate and Policy Making’, 
attracted considerable Community and international 
attention. Expert panels comprising senior political 
leaders, eminent scientists, international experts, 
leading decision and opinion formers from across 
European government and civil society engaged in 
presentation and debate over two days, with more than 
500 participants representing a wide spectrum of 
stakeholder views and expertise from across Europe. 
The conference proceedings will be published on-line, 
with a follow up focus group on the way forward 
planned for early 2004 .
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
13 (b)            the Commission will promote awareness of key 
scientific paradigms underlying regulatory 
oversight, within their respective fields, the 
European Food Safety Authority and the 
European Agency for the Evaluation of the 
Medicinal Products will play an important role in 
general risk communication
         The European Agency for the Evaluation of the 
Medicinal Products is undertaking a broad risk 
communication effort with an informative and accessible 
website (www.emea.eu.int)
        the European Food Safety Authority is now fully 
operational and has commenced its work on risk 
communication
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
Societal scrutiny and dialogue
2002
onwards
2002
onwards
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13 (c)            the Commission encourage public debates on 
biotechnology between scientists, industry and 
civil society 
Specific measures have been taken by the Commission 
in this regard. In particular:
           In the framework of the European Group on Life 
Science (EGLS)'s  Life Sciences Discussion 
Platforms, the Commission has organised the 
conference 'Towards Sustainable Agriculture for 
Developing Countries: options from Life Sciences 
and Biotechnology'
           A call for SSAs to support life sciences 
discussions platforms, citizen’s networks as well as 
initiatives to improve the science communication 
process with the involvement of the media, is currently 
open.
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
        Several projects involving consumers platforms 
and/or other public discussion forums, including pilot 
citizen's networks, are ongoing under the Quality of 
Life FP5 program 
           Under the aegis of the EGLS, the encounter  
Modern Biology and Visions of Humanity was 
organised in Genoa on 22-23 March 2004.                                    
           A citizen’s network and experts Symposium on 
"Biotechnology: possibilities, risks, ethics and 
society" will be organised in the frame of the Science 
Generation project in August 2004.
        Initiatives of public perception monitoring have been 
regularly supported, starting from FP4
           The planned European web-portal and the 
Commission's web-site that should provide a broad 
entry platform into the Commission's work on 
biotechnology (see Action 8), should present an 
improved opportunity for stakeholders and citizens to 
express their views.
            Under the Science and Society Action Plan, a 
study was launched and a conference Governance of 
the European Research Area: The Role of Civil Society 
took place in June 2003. Findings of the study and 
inputs from the conference were merged into 
Commission’s work programme for 2004.
           Following the recommendations of the EGLS 
workshop Life Sciences and the Media, a series of 
specific support actions towards improving the science 
communication process with the involvement of the 
media are being called. In the first part of 2004, 
training courses for Journalists (established 
journalists and students/young professionals) on the 
topic of Risk Governance and Risk Communication will 
be organised. The courses are organised jointly by the 
Commission and the European Journalism Centre.
2002
onwards
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14 The Commission will 
           strengthen and focus Community support for 
research into socio-economic and ethical issues 
and dissemination of results, including criteria for 
assessing the benefits of using biotechnology in agri-
food production, to facilitate future reporting and to 
provide a good basis for societal decisions on the 
application of biotechnology and life sciences.
           program research support to a more systematic 
mapping of benefits and disadvantages/risks 
which should include a strong component for 
dissemination of information and debate.
           A network on ethical, legal and social aspect in 
food research has been established among projects 
funded under Priority 5 Food quality and Safety  in 
order to exchange best practice for integrating ELSA in 
research projects, develop joint activities across 
projects, promote ELSA in food and agriculture 
research in candidate countries and develop links to  
local, regional, national and international activities.
           Experts in ethics and social sciences are 
actively participating in research projects . It allows  for 
mutual education and dialogue and ensures that 
ethicists have the means to continuously assess the 
societal relevance and adequacy of their analysis and 
evaluation;
           Stakeholders’ conferences will be organised 
providing at European level a bottom-up approach to 
help the process of consensus –forming around best 
ethical conduct involving academia, the professional 
networks and societies, industry, consumers, patient 
organisations  etc;
Commission
           A study on national, international and 
professional training material for ethics in research 
was launched in 2002.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
           A study on training programmes in ethics in 
research established in scientific faculties across 
Europe has been conducted.
           ensure that ethical, legal and social implications 
are taken into account at the earliest possible 
stages of Community supported research by means 
of funding bioethics research and of providing an 
ethical review of research proposals received. 
           All applicants under FP6 are requested to address, 
the potential ethical aspects of the proposed research 
regarding its objectives, the methodology and expected 
results. 
               A specific ethical review has been 
implemented for proposals dealing with specific and 
sensitive issues such as the use of banked or isolated 
human embryonic stem cells in culture, human foetal 
tissue or cells, non human primates, animal cloning, 
human beings, genetic information etc. The 
recommendations from the ethical review are taken 
into account in the negotiation of the projects.
Developing life sciences and biotechnologies in harmony with ethical values and societal goals
2002-06
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  In accordance with the Council minutes of 30.9.2002 
several actions have been taken by the Commission  
►  a report on human embryonic stem cell 
research was published on 3 April 2003( 
SEC(2003)441) and  a public institutional seminar 
on the subject was organised on 24 April 2003.    
►in July 2003 guidelines on human embryonic 
stem cell research in the context of FP6 were 
proposed, however these guidelines were not adopted 
by the Council.  
► procedural modalities for research activities 
involving banked or isolated human embryonic stem 
cells in culture to be funded under FP6 were adopted   
(1) COM(2002) 27 of 23 January 2002 
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15 The Commission will
           propose to enhance the role of the European 
Group on Ethics
        launch a separate consultation of the other 
Community institutions on possible structural and 
procedural improvements
           The role of the European Group of Ethics (EGE) 
has been enhanced by establishing closer 
collaboration with Commission services, and by 
increasing exchanges with other institutions namely 
with EP.
           Following the EP resolution of the Commission 
strategy on life sciences and biotechnology, the 
Commission intends to propose a modification of the 
mandate of the EGE to allow the EP and Council to 
be involved in the nomination of the members of the 
group.
ethical bodies, 
legislatures, 
Commission
           promote collaboration between Community, 
national and local levels by promoting networking of 
national and local ethical bodies and elected 
representatives
           The EGE concretely reinforced exchanges and 
collaboration with national ethics committees (NEC) by:
► publishing a newsletter "Ethically speaking" 
reporting on recent activities of NEC and facilitating 
contacts,
► inviting NEC at EGE meetings to present their 
reflection on issues of common interests,
► organising each semester a common working 
meeting with the NEC of the country chairing the 
Presidency,
► intiating bilateral meetings with NEC of acceding 
countries
       
           In the context of the Science and society action 
plan the Forum of the Presidents of the National 
Ethics Councils has been created in  December 2002 
and met for the first time in Athens in July 2003 and 
again in Rome in December 2003.    
           A directory of local ethics committees has been 
collected in the 33 countries of ERA. 
  The Forum of the Presidents of the National Ethics 
Councils will meet again in 2004 under the Irish and 
Netherlands Presidency.
        A conference  for and with Local ethics committees  
is planned for end 2004.
        organize a network of academic and professional 
experts for ad-hoc advice on specific socio-
economic aspects.
        Networks of academics and experts have been set 
up by the Commission to address socio-economic 
aspects of biotechnology, as the European Group on 
Life Sciences set up in April 2000,  to meet the need 
of high level advice on Life Sciences and 
Biotechnology.
           A network of local animal welfare committees 
is currently being established. 
           A conference on animal experimentation is 
planned for 2005 . The Council of Europe is expected 
to join this initiative.
2002
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16 The Commission
  will develop, jointly with the European 
Parliament, outreach measures to inform about 
the analysis of ethical issues at the EU level. 
           the biosociety web-site 
(http://europa.eu.int/comm/research/biosociety/index_e
n.htm) has been constructed to promote the 
dissemination of the results of EC funded  research 
projects into the ethics of Life Science and 
Biotechnology, and to contribute to inform the ethical 
debate. 
  
           European Information Network Ethics in 
Medicine and Biotechnology " EURETHNET" 
(http://www.eureth.net.) has been funded under the  
Quality of Life Programme" (FP5)
         a feasibility study has been launched under the 
Science and Society action plan to  explore  how  to 
further develop an efficient  "European Information and 
Documentation system on Ethics in science" 
European 
Parliament, 
Member States, 
regions, industry, 
institutions, 
Commission
2002
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        will work with public and private partners, to 
identify areas where it is possible to establish 
consensus on ethical guidelines/standards or best 
practice. Areas might include stem cell research, 
biobanks, xenotransplantation, genetic testing and 
use of animals in research. Such guidelines could, 
when appropriate, take the form of self-regulatory 
initiatives in the scientific community and industry.
           The Commission continues to up-date the  
surveys regarding national legislations in relation to 
xenotransplantation, human embryonic stem cell 
research  and biobanks. These surveys allows to 
analyze best practice and provide a first step towards 
preparations of guidelines. 
           A High level Strata Group has been set up in 
2003 to discuss methodologies to analyze underlying 
ethical values in the ERA.
                                                                                                                                                                                                                   
           A high level Strata Group  on Genetic testing, 
composed of  representatives from industry,  NGO, in 
particular patient organizations and scientists and 
social scientists,  was set up in 2003 to discuss  the 
ethical implications in genetic testing.
           The opinions of the EGE and the work in Council 
of Europe are other important documents in this 
respect.
           The High Level Strata Group  will deliver a report 
by the beginning of 2004. A proposal for a 
EUROBAROMETER  on ETHICS is under 
consideration.
           The high level Strata Group  on Genetic testing will 
publish a report early 2004 and a stakeholder 
conference will take place in spring 2004.
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17            to develop research and pilot projects to clarify 
the need, and possible options, for agronomic and 
other measures to ensure the viability of 
conventional and organic farming and their 
sustainable co-existence with genetically modified 
crops. 
            A round table on co-existence was organised by 
the Commission in April 2003. 
        a Commission Recommendation 2003/556/EC on 
guidelines concerning co-existence was adopted on 
23 July 2003.
        A 1st European Conference on the co-existence 
of Genetically Modified Crops with conventional 
and Organic Crops took place 13-14 November in 
Denmark. 
           A national debate was organised in UK. Details 
are available at www.gmnation.uk
               A new study on co-existence is on-going, 
aimed to analyse new cases studies on this issue, with 
special focus on seed production. The study includes 
analysis of the economic costs related to the 
introduction of different farming practices. Final results 
are expected by end 2004.
        the Commission will enhance its co-ordination role 
as defined by Directive 2001/18/EC.
           the Commission will report to the Council and to 
the EP on experience gained in the MS, including, as 
appropriate, necessary steps to take.
Member States, 
professional 
associations, 
other operators, 
Commission
           To launch a new action program for the 
conservation, characterization, collection and 
utilization of genetic resources in agriculture in the 
Community.
           The Community programme on the conservation, 
characterisation, collection and utilisation of genetic 
resources in agriculture has been adopted, with an 
estimated overall cost up to €10 million for the period 
2004-2006 (COM(2003) 817)
        This programme aims to help maintain biological
diversity, improve the quality of agriculture products,
contribute to diversification in rural areas and reduce
inputs and agricultural production costs by promoting
sustainable and rural development.
Demand-drive applications through informed choice
2002
onwards
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18            to speed up the adoption of the three 
legislative proposals, revising the Community 
pharmaceutical legislation
           On 17.12.2003, the European Parliament has 
adopted the compromise amendments negotiated 
with the Council on the Pharmaceutical Review 
package (COM(2001)404 Final). This paves the way 
for its adoption in the first months of 2004. 
           The review consists of 3 proposals, i.e. one 
regulation dealing with the Community centralized 
procedure for the authorisation and supervision of 
medicinal products and establishing the European 
Medicines Agency, and two directives modifying the 
existing codes in the field of human and veterinary 
medicinal  products which were adopted by the 
Commission on 26.11.2001
 European 
Parliament, 
Council
19          To speed up the adoption of the two following
legislative proposals:
        Proposal for a European Parliament and Council
Regulation on Traceability and Labelling of
Genetically Modified Organisms and Traceability
of Food and Feed derived from Genetically
Modified Organisms.
           The two proposals were adopted by the European 
Parliament and Council: 
► Regulation (EC) N°  1830/2003 on traceability and 
labelling of GMOs and of food and feed produced 
from GMOs
               see action 21 for implementing measures of 
both Regulations.
European 
Parliament, 
Council
        Proposal for a European Parliament and Council
Regulation on Genetically Modified Food and
Feed.
► Regulation (EC) N°  1829/2003 on GM food and 
feed
Short-term regulatory action
Pharmaceutical legislation
2002
2002
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20         To finalize the legislative proposals which
have already been announced, such as initiatives
concerning GM plant propagating material, 
environmental liability and the implementation of
the biosafety protocol. 
            The Commission has adopted a Proposal 
concerning the environmental liability (COM(2002)17 
final of 23 January 2002). The Council and the EP 
reached an agreement in February 2004..
 
            Regulation (EC) No 1946/2003 of the European 
Parliament and the Council on the transboundary 
movements of GMOs was adopted on 15 July 2003. It 
is applicable as of 25 November 2003.
            The final approval by the two institutions is 
scheduled in March 2004.
European 
Parliament, 
Council, 
Commission
            The Cartagena Protocol on Biosafety entered 
into force on 11 September 2003.
           Thresholds for the adventitious presence of 
authorised GMOs in non-GM seeds will be finalized 
under Article 21(2) of Directive 2001/18/EC during 
2004. Similar thresholds will be then adopted under 
Seeds Directives.
2002-03
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21         To ensure that legislation is enforced in a
uniform and effective way across the Community
and to adopt appropriate implementing measures
required under relevant legislation, including the
necessary guidance for detection and sampling
methodology
In order to ensure uniform and effective enforcement of 
EC legislation,
                several implementing measures  have been 
adopted
► Council Decisions 2002/812 and /813/ EC 
establishing the Summary Notification Information 
Format Parts C and B,
► Commission Decision 2002/623/EC establishing 
guidance notes supplementing Annexes II and VII to 
Directive 2001/18/EC, 
► Council Decision 2002/811/EC establishing the 
guidance notes supplementing Annex VII to Directive 
2001/18/EC,
► Council Decision 2003/701/EC establishing a format 
for presenting the results of the deliberate release into 
the environment of GM higher plants
► Commission Regulation No 65/2004 on the 
establishment of unique identifiers
► Commission Decision 2004/204/EC laying down 
detailed arrangments for the opeartion of the registers 
for recording information of genetic modifications in 
GMOs
 Other implementing measures required by the new 
legislative framework are under consideration:
               Guidance for sampling and detection of 
GMOs and GM food and feed. A formal Commission 
Reccomendation will be adopted in early 2004
           Implementing rules for Articles 5, 8, 17, 20 and 
47 of Regulation 1829/2003
           A proposal for a Commission Regulation on a 
protocol for sampling and testing of seed lots of 
non-GM varieties for the presence of GM seed will be 
put forward together with a proposal for a Commission 
Directive amending the annexes of the different seed 
Directives.
Commission
Implementation and enforcement activities
2002-03
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
         the JRC of the Commission continues to co-
ordinate a network of laboratories responsible for 
GMO testing from Member States and third countries. 
The main objective of this network is to contribute 
effectively to the European harmonization and 
standardization of means and methods for sampling, 
detection, identification and quantification of GMOs 
and GM products. The JRC is also providing certified 
reference materials.
           The proposal for GM Food/Feed establishes that 
the JRC is the Community Reference laboratory to 
be assisted by the “European Network of GMO 
laboratories"
        To establish a molecular register that is
accessible to the public, containing information on
events of genetic modification.
           The creation of a molecular register of known 
GMO molecular and biological data has begun 
22            To report on the feasibility of options to 
improve further the consistency and efficiency 
of the framework for authorizing GMO’s for 
deliberate release into the environment, including 
a centralized Community authorization procedure.
           A  study  was launched on 30 July 2003.             This study is aimed at preparing the 
Commission's report to the other EU institutions.
Commission
23            To support the development of methodologies 
for monitoring potential long-term environmental 
impacts of GMO’s as compared with conventional 
crops, and methodologies for the monitoring of 
effects of genetically modified food and feed as 
compared with conventional food and feed. With 
the establishment of the European Food Safety 
Authority, the work on the early identification of 
emerging risks will be reinforced and upgraded.
  a working group for the development of specific 
sets of monitoring criteria for individual groups of 
GMOs and for different transgenic phenotypes has 
been set up.
           Short and medium term actions concerning the 
development of methodologies for post-marketing will 
be developed in consultation with European Food 
Safety Authority by 2003
        Council Decision 2002/811/EC (see action 21) will 
contribute to monitor potential long-term environmental 
impacts of GMOs.
Commission
Specific long term regulatory action
2003
2002
onwards
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Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
24            The Commission should continue to play a 
leading role in developing international 
guidelines, standards and recommendations in 
relevant sectors, based on international scientific 
consensus and, in particular, push for the 
development of a consistent, science-based, 
focused, transparent, inclusive and integrated 
international system dealing with food safety issues.
           The Commission continues to play a leading role 
in Codex Alimentarius, where it has become a full 
member, OECD and under the biosafety protocol  
with a view to develop international guidelines, 
standards and recommendations on food safety and 
biotech issues.
        An EC-OECD colloquium was  organised - jointly 
by the Commission and the OECD, in Brussels on 6 
October 2003 – as an international forum for early 
discussions towards a world-wide harmonisation of 
genetic testing quality assurance. 
           Specific support actions are being call for under 
FP6 to facilitate bi-regional dialogues and bi-lateral 
international cooperations in life sciences and 
biotechnology.
Commission
A European agenda for international collaboration
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
25 (a)            the Commission will in cooperation with 
Member States support the redefining of national 
research towards an appropriate mix of 
traditional techniques and new technologies, 
based on priorities developed with local farmers. 
           This action is addressed in the Commission 
Agricultural Research for Development (ARD) 
strategy document, elaborated in close collaboration 
with the Member States, available at the following 
address: 
http://europa.eu.int/comm/development/rurpol/outputs/
ard/ard.pdf
           On 30-31 January 2003, the Commission 
organized a Life Sciences Discussion Platform: 
Towards sustainable Agriculture for Developing 
Countries, aiming to address the potential, benefit and 
risks of life sciences and biotechnology for sustainable 
agriculture in developing countries Conclusions and 
recommendations are available at the following 
address:http://europa.eu.int/comm/research/conferenc
es/2003/sadc/index_en.html
        As a follow-up of the above Discussion Platform, the 
Commission has invited for a specific support action 
aiming at contributing to an  International consultative 
forum on life sciences and biotechnologies for 
developing countries.
           Implementation of this approach through the Sub 
Regional Organizations SADC / SACCAR program is 
under preparation (estimated amount: 15M€) with the 
participation of the Member States through European 
Initiative for Agriculture Research for Development
           A programme will be signed by mid-2004 with the 
Global Forum on Agricultural Research  (GFAR) 
aiming at enabling greater stakeholder participation. 
The Commission is funding a project titled 
"Strengthening the Functional Linkages between Civil 
Society Organizations (CSOs) and National Agricultural 
Research Institutions (NARIs) for Effective Agricultural 
Research for Sustainable Development".
This initiative focuses on capacity building of 
participating farmer’s organisations and NGOs involved 
in ARD in sub-Saharan Africa and at reinforcing the 
involvement of the participating beneficiaries in ARD 
activities and decision-making processes at the 
national and regional levels. 
Member States, 
Commission
Europe's responsibilities towards the developing countries     Agriculture
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
25 (b)           the Commission will in cooperation with 
Member States support the establishment of 
effective research partnerships between public 
and private research organizations in developing 
countries and in the EU, and the adequate capacity 
and infrastructure for developing countries to 
enter into such partnerships, in accordance with 
international commitments under the Conventions.
           Partnerships, capacity building and physical 
infrastructures are being provided through various 
financial instruments, such as on-going Commission 
research support projects and ARD programs. The 
FP6 will pursue these efforts, particularly through its 
international dimension.
            South-South and South-North Partnerships will 
be strengthen through the implementation of 
Competitive Funds at national level, subregional level 
(see action 25a), regional level (FARA, FONTAGRO, 
etc.), and at global level (GFAR, CGIAR challenge 
programs). 
        The 5th Global Forum on Bioethics will take place 
in April 2004 in Paris. The Commission is participating 
in the steering committee together with the  MRC, the 
Welcome Trust, NIH Fogarty Centre, INSERM, WHO. 
The topic will be “Sharing the benefits from research 
in developing countries: equity and intellectual 
property” 
Member States, 
Commission
25 (c)            the Commission will in cooperation with 
Member States support sub-regional, regional 
and international organizations, in particular the 
International Agricultural Research Centers.
           The Commission and the Member States are 
working together through European Initiative for 
Agricultural Research for Development (EIARD)  to 
elaborate common positions on and participation in the 
Consultative Group On international Agricultural 
Research (CGIAR) policy, governance and 
management structures, as well as to co-ordinate 
respective supports.
           The proposed EC support to the  CGIAR for the 
period 2002-2004 has been endorsed by the EU 
Member States in the Foods Aid / Food Security 
Committee at the end of May 2002 and will amount to 
22 M€ per year.
           the list of CGIAR projects to be financed by the EC 
in 2004  has been reviewed with the EU Member 
States in September 2003.
           Regular participation of the Commission in the 
European Initiative for Agriculture Research for 
Development (EIARD) meetings is ensured.
        Annual contracts will be prepared and signed by the 
Commission with the Consultative Group On 
international Agricultural Research (CGIAR) Secretariat 
/ World Bank for the mobilization of the EC support 
2002-04. 
        Priority areas of EC support and implementation 
modalities are detailed in  EC strategy document 
"GCRAI: éléments de stratégie" available on 
Commission website at 
http://www.cc.cec/home/dgserv/dev/body/theme/docs/
B4/ARD%20CGIAR%20Strategy%20FR.pdf)
            The next 3-year allocation to the CGIAR (2005-07) 
is under preparation.
Member States, 
Commission
2002
onwards
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
26 (a) The Commission and the Member States will support 
the conservation and sustainable use of genetic 
resources in developing countries and their 
equitable sharing of benefits arising from their use 
by:
           supporting the development and enforcement of 
effective measures to conserve, to use 
sustainably and to provide access to genetic 
resources and traditional knowledge, as well as to 
share equitably the benefit arising from them, 
including income generated by intellectual property 
protection. Support for local communities is vital to 
conserve indigenous knowledge and genetic 
resources.
           At the WTO : Commission actively participated in 
review of Article 27.3(b) of the Trade Related 
Intellectual Property (TRIPs) Agreement and, in the 
context of the DDA, in the working program mandated 
by para. 19 of the Doha Ministerial declaration. A 
Communication on these issues, which was 
submitted by the Commission to the TRIPs Council on 
16 September 2002 (ref. IP/C/W/383), was welcomed 
by several deveoping countries as a useful contribution
           At the CBD : the Commission and the MS were 
pro-active negotiators, under the Convention on 
Biological Diversity, of the Bonn Guidelines on 
Access to Genetic Resources and Benefit-sharing 
adopted on 19 April 2002. On 23.12.2003, the 
Commission adopted a Communication on the 
implementation of the above Guidelines and is 
currently working on its follow-up measures. The 
Commission has also been an active negotiator of the 
terms of reference for an International Regime on 
Access and Benefit-sharing, at the 7th Conference of 
the parties of the CBD (Kuala Lumpur, 22-27.2.2004).
           The Commission will continue its active 
participation in the debate on TRIPS and Biodiversity in 
the WTO.
         An international action contributing to the 
implementation of the Convention on Biological 
Diversity for international equitable access and benefit 
sharing of microbial resources is being negotiated 
under FP6 and the Commission has invited for a 
specific support action aiming at establishing 
Networking of European and International 
Research on issues related to conservation, 
management and sustainable use of genetic resources 
for food and agriculture (deadline 5 February 2004)
           The Commission will streamline the issue of 
access and benefit-sharing in the on-going revision of 
the EC Biodiversity Action Plan on Economic and 
Development Co-operation.
Member States, 
Commission
           At the WIPO : Commission and Member States 
are active participants in the Intergovernmental 
Committee  on Intellectual Property, Genetic 
Resources, Traditional Knowledge and Folklore. 
Europe's responsibilities towards the developing countries      Genetic resources
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
           At the FAO : Commission and Member States 
played key role in the adoption of the International 
Treaty on Plant Genetic Resources and provides 
input to the current dialogue on the conditions for 
ABFS in the context of the IT with an aim to agree on a 
standard Material Transfer Agreement.
26 (b)            supporting the participation of delegates from 
developing countries in the negotiations of 
relevant International Conventions. 
           Financial resources are available in the envelope 
"Intra-ACP resources 9th European Development 
Fund (EDF 9) to contribute to this objective. 
        An additional limited contribution for supporting 
capacity building and the participation of ACP 
Representatives in International Conventions is under 
consideration.
        Ad hoc contributions for the participation of 
delegates from developing countries to specific 
meetings of the Convention on Biological Diversity and 
of the Cartagena Protocol on Biosafety are provided for 
in 2004.
Member States, 
Commission
26 (c)            supporting measures to promote greater 
regional co-ordination in legislation to minimize 
disparities in access, benefits and also trade in 
products derived from genetic resources, in 
accordance with international commitments
           A Commission's study "Benefits, needs, 
constraints and recommendations for development 
and use of biotechnology in developing countries" 
is under preparation. The objective of this study is to 
list recommended standards and guidelines to promote 
the safe and effective development and use of green, 
white and red biotechnology in developing countries, 
based on their autonomous choice and on their 
national development strategies. Stakeholders will be 
consulted on the terms of reference in 2004.
           Several African sub-regional research 
organizations (e.g. ASARECA, SACCAR and 
CORAF) could be well placed to work on these 
subjects (i.e. national and regional policy processes 
and coherence). 
           EC financial resources mobilized  for Agricultural 
Research for Development (ARD)  at sub-regional level 
(respectively €28, 19 and 20 M), in close collaboration 
with the Member States mainly through European 
Initiative for Agricultural Research for Development 
(EIARD), could be partly utilized for this purpose. 
Member States, 
Commission
2002
onwards
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
27            The Commission and the Member States 
should work with the international community to 
concretize the commitment to research to 
combat HIV/AIDS, Malaria, TB and other main 
poverty-related diseases and also identify 
effective measures to support developing countries 
in establishing the structures needed to deploy a 
health policy.
           The European and Developing Countries 
Clinical Trials Partnership (EDCTP) was adopted in 
June 2003 and will be fully operational during the first 
half of 2004, whereupon it will consider applications for 
funding or co-funding of clinical trials from the private 
and public sectors, including industry, organisations 
and individuals from Europe, developing countries and 
elsewhere.
           Improved co-ordination of research activities 
between Member States will increase the impact and 
efficiency of research efforts. With the establishment of 
the EDCTP the fragmentation of European research 
efforts can be overcome and also be translated into 
clinical interventions that are applicable in the 
Developing Countries. The EDCTP has a target budget 
of € 600 million. The Community will contribute one 
third of the budget via the 6th FP, whereas another € 
200 million will be provided by Member States and 
Norway. The remaining € 200 million will be sought 
from private sources, R&D industry, foundations, 
charities and Community development funds (e.g. 
EDF).
Member States, 
Commission
           An international dialogue and training courses 
have been organised, together with the National 
Institute of Health (NIH), aiming to assist in capacity 
building for the ethical assessment of research projects 
and clinical trials in developing countries. In 2002 and 
2003 workshops have been organised Seoul/South 
Korea and in Mali/Bamako and in Kampala/Uganda.  A 
teaching  manual for conducting clinical trials in 
developing countries have been prepared in the 
context of an EC funded project 
(http://www.ethica.uib.no/level/ctc.html).
           A further workshop is planned in Egypt.
           The Program for Action against AIDS, malaria 
and tuberculosis has progressed on the main issues 
of impact, affordability and research.
Europe's responsibilities towards the developing countries     Health
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
28
(a),(b),(c),(e)
 
To support:
           the safe and effective use of modern 
biotechnologies in developing countries, based on 
their autonomous choice and on their national 
development strategies.
           measures to increase the capacity of 
developing countries to assess and manage risk 
for man and the environment, under conditions 
prevailing in the country.
           the development of appropriate administrative, 
legislative and regulatory measures in the 
developing countries, for the proper 
implementation of the Cartagena Protocol.
           that the international regulatory requirements 
remain manageable by developing countries, so as 
not to impede their trade and production prospects.
           A Commission's study "Benefits, needs, 
constraints and recommendations for development 
and use of biotechnology in developing countries" 
is under preparation. (See action 26c) 
           The Commission has been actively involved in the 
works of the Intergovernamental Committee of the 
Cartagena Protocol (ICCP) in preparation of the entry 
into force of that Protocol. The Protocol sets out simple 
requirements which allow countries to make informed 
choice on the import of GMOs.
           the Commission will finance in 2004 a workshop 
on capacity building concerning the 
documentation requirements for the transboundary 
movements of GMOs under the Cartagena Protocol of 
Biosafety.
           A platform for bi-regional co-operation with 
Asia in the field of food quality and safety research is 
being negotiated and the Commission has invited for a 
specific support action aiming at establishing Bi-
regional co-operation platforms for food quality and 
safety research with Latin America and/or African-
Caribbean-Pacific ACP countries.
           The Commission will streamline the 
ratification/implementation of the Cartagena Protocol 
on Biosafety in the on-going revision of the EC 
Biodiversity Action Plan on Economic and development 
Co-operation.
Commission
28 (d)            that international research on social, 
economical and environmental impacts are 
effectively adapted to take into account conditions 
prevailing in developing countries and that the 
findings are subsequently disseminated to them in 
an appropriate format.
           Impact monitoring and subsequent 
recommendations are fully integrated in the EC 
supported research programs, being at national, sub-
regional, regional and global levels
Commission
Europe's responsibilities towards the developing countries   Responsible and careful use
2002
onwards
2002
onwards
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29 (a)
The Commission will enhance:
           the general foresight function across 
Commission services, and in particular its role in 
technology foresight through its Institute for 
Prospective Technological Studies (IPTS), for early 
identification of newly emerging issues and of 
elements of a policy response 
        The Commission's Joint Research Center (JRC), 
to which IPTS belongs, published in 2003 two 
prospective studies on emerging biotechnology 
applications and issues: Human tissue engineering 
and quality assurance and harmonistaion in 
genetic testing.
               IPTS foresight and anticipation studies on 
animal cloning, aquaculture, pharmacogenomics, 
nanodevices in medical diagnostics and 
therapeutics,  the use of GMOs in agriculture are on-
going or will start in 2004.
Commission, 
Member States
29 (b)            its monitoring and review function to assess
- the relevance, coherence and effectiveness of 
legislation and policy
- the extent to which policy objectives are achieved 
and legislation enforced 
- the societal and economic impact of legislation 
and policy measures
In pursuit of these objectives and to further 
strengthen policy coherence, the Commission 
           The Commission Biotechnology Steering 
Committee (BSC) consisting of the most directly 
involved cabinets and services has been set up and 
has met regularly since 2001.  The mandate and 
composition of the BSC has been recently reviewed in 
order to reinforce continuous co-ordination amongst 
the 17 Commission services which have an interest in 
Life Sciences and Biotechnology.
Commission, 
Member States
Implementation and coherence across policies, sectors and actions
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
timeframe
2002 
onwards
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
timeframe
29 (c )            will reinforce continuous co-ordination between 
its services and calls upon Member States to also 
provide enhanced foresight/review functions and a 
coordinated interface for a dialogue on these 
issues.
Commission, 
Member States
30            The Commission will present a regular Report 
on Life Sciences and Biotechnology to monitor 
progress and indicate possible specific proposals to 
ensure policy and legislative coherence. The report 
will draw on the conclusions under actions 10 and 
29.
           The first annual Report was adopted on 5 March 
2003 (COM(2003) 96). 
           In its conclusions, the European Council in 
Barcelona asked Council and the Commission to 
develop the detailed measures to implement the 
approach proposed and report on progress in good 
time for the 2003 Spring European Council. 
Commission
2003
onwards
2002
onwards
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ANNEX 2 
Competitiveness in Biotechnology Advisory Group – Report 2003 
Introduction 
The Commission has appointed the Competitiveness in Biotechnology Advisory Group with 
Industry  and  Academia  in  accordance  with  Action  10b  of  the  Action  Plan.  The  Group’s 
mandate is to assist the Commission in identifying issues affecting Europe’s competitiveness. 
The members of the Group represent all major fields of biotechnology and the spectrum from 
entrepreneurial  companies  to  large  companies.  In  addition,  they  also  stem  from  different 
European regions. 
The Group has the mandate to provide input into the Commission’s annual report on the 
implementation of the Strategy. In 2003 the group chose to concentrate on financial and 
regulatory issues. The following report is the outcome of those deliberations. It is the advice 
of the Group and does not represent the views of the Commission. 
I. Financial opportunities, issues, obstacles 
Entrepreneurial  biotechnology  companies  are  faced  with  the  same  pressures  as  other 
innovative companies, but which for biotech companies are often more acute. Three main 
areas require attention to boost the financial environment for biotech companies: protecting 
intellectual property rights, boosting finance, liquidity and capital markets in Europe, and 
research funding through public/private partnerships.  
For fast and effective improvements, the entrepreneurial biotechnology community expects 
policy changes at a national level rather than at an EU level. Many of the recommended 
actions are directed therefore to Member States rather than the Commission. 
Intellectual Property Rights 
No  other  business  area  is  as  dependent  on  protecting  their  intellectual  property  as 
biotechnology. Strong and stable IP protection of biotechnological inventions is a prerequisite 
for any type of funding at any stage. It is a key decision-making factor for investors seeking 
to protect their investment, particularly in the start-up phase. It is also key in a company’s 
valuation as it is looking to go public. Investors will keep judging the value of biotechnology 
ventures by the quality and robustness of their IP. 
There are three major issues in intellectual property vital to the development of biotechnology 
in Europe: the Community Patent, the Biotech Patent Directive (98/44) and the patenting 
policy of universities and other public research centres.  
The  Community  Patent,  as  currently  proposed,  will  be  better  than  before  but  not  good 
enough by far to outclass our competitors. Furthermore, crucial aspects of it are unlikely to 
come into force until after 2010, when the EU is already supposed to be the most competitive 
economy in the world.   
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Recommendation 
CBAG calls for the introduction of an EU-wide Community Patent system which is 
legally secure, cost-effective and simple-to-obtain. 
•  A unitary jurisdiction at first and second instance, with highly qualified 
expert judges, so as to reach legal certainty and streamlined enforcement. 
•  A language regime that is restricted to an absolute maximum of the three 
EPO  official  languages,  English,  German  and  French,  with  one  single 
authentic text, that of the language in which the patents was granted. 
•  A system where patent applications are fully processed by the European 
Patent Office (EPO) 
•  Transition periods reduced to an absolute minimum so that entrepreneurs 
may  reap  immediate  benefit  from  the  simpler  and  cheaper  procedures 
offered by the regulation. 
The Directive 98/44 on the protection of biotechnological inventions was adopted in 1998 
after lengthy discussions and was to be implemented in all Member States by 30 July 2000. 
Yet to date just eight Member States have implemented it. 
Discussions mostly relate to the clause on gene patenting (Art. 5). The European Parliament, 
for instance, considers recommending that the Commission amend Article 5 to exclude from 
patentability the total or partial sequence of an isolated human gene. Yet, the Directive as it 
currently stands does not go further than any US or Canadian rules. It protects the dignity of 
the human body while allowing useful inventions to be developed. It prohibits making profits 
from the human body and its elements, as stated by Article 3 of the Charter of Fundamental 
Rights. It is clear in what it does and does not permit and no basic deficiencies have been 
documented to date.This sends the wrong signals to companies and investors, casting doubt 
over whether a useful invention might be held up, or worse may not be granted at all.  
Recommendation 
CBAG calls for the swift and loyal, one-on-one implementation of the EU Directive 
on the legal protection of biotechnological inventions (Directive 98/44) 
The  patenting  effectiveness  of  European  public  research  is  lagging  that  of  the  US.  Recent 
findings  at  Leuven  University  show  that  US  patents  borrow  much  more  from  European 
science than the other way around. Yet it is through patents rather than publications that value 
is created for the institution and the inventor and, eventually, for environment, people and 
jobs.  Rules  governing  who  benefits  in  Universities  from  a  patent  are  an  important  issue. 
Granting personal or collective ownership to university researchers of the intellectual property 
they generate and entitling them to commercialise their findings are an important incentive for 
entrepreneurial  biotech  in  the  countries  where  these  principles  are  applied  (e.g.  Finland, 
Sweden). 
Recommendation 
CBAG calls for better understanding within the Academic community of how to turn 
applied research into innovative products. Best practice from Sweden and Finland in 
academic incentives to patent should be rolled out across Europe.  
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Financing, liquidity and capital markets 
Half of all economic growth is generated by research and innovation, which spur employment 
and economic wealth. Public and private sector research needs to be stimulated to achieve this 
growth. To raise its level of innovation, Europe must increase R&D spending to 3% of GDP 
and drastically raise employment levels between now and 2010 (Lisbon goal). The public 
sector will not achieve this alone and Europe needs to boost private sector research, especially 
in areas with a high growth potential. Young innovative biotech companies have that growth 
potential and remain a largely untapped source of innovation and employment growth. 
Lack of funding is a major obstacle to the development of entrepreneurial biotech companies. 
Low exit opportunities for investors keep them from feeding follow-on funds and seed funds 
alike, thus causing a vicious circle. Europe must create optimal conditions for investors to 
cash in their investments and liberate funds for new ones. Policies stimulating investment in 
young innovative companies should be jointly prepared by the entrepreneurial community and 
the government.  
Young Innovative Company (YIC) status, with tax and labour tax exoneration, represents 
an investment with a high economic return. A French study shows that the resulting economic 
growth would yield net fiscal revenues in just 3 years.  
There are huge disparities between Member States, in social costs and in the cost of doing 
business in general. If applied throughout Europe, YIC would put innovative companies at a 
stroke on the same starting block.  
A specific YIC law is  discussed in the French parliament for implementation as early as 
1.1.2004. To qualify, companies must be less than 8 years old and spend more than 15% of 
their total expenses on R & D. The key features of the law would be: 
•  social contributions (for all staff, not only R&D workers) waived for 6 years and 
reduced by half for a further 3 years 
•  no corporate tax for the first 3 years, reduced by half for a further 2 years 
•  no local taxes 
•  no capital gains tax 
•  tax reduction on stock options 
EuropaBio’s  Emerging  Enterprises  Board  members  are  discussing  similar  measures  with 
other national governments.  
Several  successful  EU  biotech  ventures  in  Europe  have  spun  out  of  large  life  science 
companies and that origin has been a main factor for their success. Where fiscal incentives for 
YICs are formulated, it is crucial that they also apply to this type of new business, even when 
the  company  which  they  spun  out  from  is  keeping  a  (temporary)  high  equity  share. 
Entitlement  to  Young  Innovative  Company  status  will  stimulate  venture  capital  funds  to 
complete and/or replace the originator company’s equity share. 
Recommendation 
The CBAG calls on EU governments to create a specific status for young innovative 
companies,  providing  tax  exemptions  to  entrepreneurs,  employees,  investors  and 
companies across Europe to reward risk with incentives and benefits.  
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Insufficient liquidity for innovative companies is a major obstacle to private investment in 
research based industries. Venture capital trapped in companies ready to go public should be 
freed up for re-investment in early stage ventures, but the only way to do so is through an 
IPO, trade sale or financial sale- a dwindling opportunity in Europe.  
Rather than multiplying competing initiatives, Europe needs to build a powerful European 
capital  market  with  fund  raising,  investment  and  exit  opportunities  for  companies, 
entrepreneurs and investors. US biotech has largely been helped by an integrated stock market 
with a critical mass of companies, investors and analysts. In 2002, US public companies had 
twice the market capitalisation of EU companies.  
The CBAG therefore welcomes the European Commission’s efforts in creating a harmonised 
equities  market  in  Europe  through  the  implementation  of  the  Risk  Capital  Action  Plan 
(RCAP)
2.  European  equity  market  fragmentation  deprives  entrepreneurs  of  a  potent 
investment motor, like NASDAQ in the US. A key cause is the existence of different and 
often conflicting national rules. Their harmonisation is therefore an urgent priority. It will 
attract  additional  capital,  create  greater  liquidity,  allow  for  automatic  multi-listing  of 
companies and eventually a merger of existing exchanges. 
Recommendation 
CBAG calls on the EU governments to achieve harmonized securities regulations by 
2004 and to work with Euronext, LSE and national markets to offer automatic multi-
listing of companies, or mergers of existing stock markets. 
Scarce Venture Capital is mainly used to support established businesses or bail out existing 
investments. The result is a lack of first round financing. Investment companies who see this 
as the shape of things to come, are restructuring their operations to assume market risk rather 
than technical risk, and prefer investing at post-development stage. Most investors expect at 
least one drug in a company’s pipeline to work so that they can exit and reinvest takings in 
new ventures, but this is rendered increasingly difficult : 40 IPO in 2000, 6 in 2001, 3 in 2002 
and no revival in sight. In addition, in many countries, a lack of confidence-inspiring national 
lead investors deters local would-be investors to join in. 
Consolidating smaller ventures into larger entities creates higher quality portfolios, but other 
means are needed to lift promising companies to an attractive level. One such solution would 
be  increased  investment  by  institutionals,  in  particular  by  pension  funds,  whose  funding 
possibilities  are  presently  limited  by  law,  despite  the  promise  of  superior  or  equivalent 
returns. Pension funds portfolios should therefore be allowed to also include VC investments 
in innovative companies. With 5% of pensions funds’ money invested in this way, this would 
add nearly 1% to GDP. As importantly, it would strongly encourage other investors to join. 
Recommendation 
The CBAG calls for greater investment possibilities for pension funds in innovative 
companies across Europe 
The European Commission Biotech and Finance Forum (BFF) found that the gap between 
seed funding and IPO is critical in several countries (e.g. Germany). With an estimated 2003 
                                                 
2  COM(2003)654 final, 4 November 2003  
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funding gap of up to €1 billion for EU biotech companies, an urgent solution is required to 
avoid destruction of value and momentum, built up during the past decade.  
Mid to late stage companies with costly clinical development programmes run the greatest 
risk and distract management from the daily task of running the business. Expansion capital 
provision needs to be addressed at all stages of company development and different skill sets 
will be required to deploy capital at different stages. Public companies for their part are often 
trading  below  their  cash  per  share  valuations,  creating  the  impression  that  the 
technology/products are worthless and that management is destroying value.  
Funding cycles for public and private companies are interrelated and should be addressed 
simultaneously. 
Recommendations 
The CBAG supports the conclusions of the Biotech and Finance Forum WG 
For private companies 
•  Conventional lead investing of larger rounds 
•  Providing ‘top up’ funds for ‘inside’ co-investment rounds 
•  Bridge financing in the form of convertible loans  
For public companies 
•  Consolidation  funds  to  foster  public-public,  public-private  or  private-
private transactions 
•  Cross-over funds to “arbitrage” valuation gaps between public and private 
companies and support consolidation 
Research funding and public-private research partnerships 
Public research is a major contributor to new ideas, jobs and economic growth, but many 
national research councils and similar bodies are seriously under-funded and need a drastic 
budget increase. Stagnating government funding gives the wrong signal to private companies 
that are considering increased R&D spending. 
Under-funding is not the only obstacle, though. University structure and culture may also 
hamper entrepreneurial off-shoots and academia-industry collaboration, two essential factors 
for turning research into marketable products and services. 
Joint projects between academia and start-ups, key to the successful take-off of many 
start-ups,  should  be  encouraged.  The  Finnish  national  technology  funding  agency,  for 
instance, provides special support to joint projects between academia and start-ups. It is no 
surprise that this country is one of the world’s most competitive nations in the OECD ranking. 
However, private/public agreements are by their nature very different from private/private 
industry agreements. The proposed new Technology Transfer Block Exemption Regulation 
(TTBER),  revising  the  current  Regulation  (240/96)  on  technology  licensing  under  EU 
competition law, will have an impact on the biotech industry and on the academia/industry 
licensing  agreements.  Such  revision  must  take  adequate  account  of  academia/industry 
licensing agreements, so as to encourage such partnerships to develop.  
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Recommendation 
CBAG  calls  for  technology  transfer  programmes  modeled  on  best  practices  to 
increase the number of private/academia spin-offs and licensing agreements and to 
ensure that such practices are adequately taken account of when considering new or 
amended EU legislation. 
Gear EU research funding programmes to SMEs. Research funding programmes are often 
too  bureaucratic,  long  and  cumbersome  for  young  companies,  with  too  many  partners  to 
manage a project. Too much effort is needed for too small a return. If grants were aimed to 
increase the competitiveness of SMEs and drive growth, then research projects should be 
much more business driven with clear milestones. SMEs need to be in full control to develop 
strategic  research  projects  for  business  growth,  as  academic  led  projects  often  fail  to 
adequately meet the business growth objectives of companies. 
Recommendation 
CBAG calls for the EU Commission and Member States to make research funding 
conditions more suitable to SMEs, to focus SME research funding programmes on 
building  growth  and  competitiveness  in  industry  and  not  to  mix  these  goals  with 
political, social, and ethical objectives which can be covered through other projects 
with appropriate funding.  
II. Regulatory issues and requirements 
In  the  Commission  Communication  Life  sciences  and  biotechnology  –  A  strategy  for 
Europe [COM(2002)27], a bold and comprehensive strategic action plan is spelled out, which 
includes  the  drafting  and  completion  of  various  pieces  of  legislation  aimed  at  enhancing 
Europe’s  competitiveness  in  the  global  marketplace,  in  line  with  the  Lisbon  2010  goals. 
However, in order to truly raise competitiveness, new or improved EU legislation must be as 
good or better than that of our main competitors, and cannot satisfy itself with being merely 
better than what was in place before. In addition, requirements for industry to comply with 
legislation should be proportionate with the objectives pursued and should strike the right 
balance between the enabling and controlling objectives. In particular, legislation should take 
due account of SMEs, which are a vital part of the biotechnology community. For them, 
requirements  and procedures which  are manageable by larger companies may represent a 
major obstacle or even a dissuasion to engage in certain activities. 
1.  Healthcare Biotechnology 
Healthcare  biotech  products  generally  enjoy  better  acceptance  than  other  biotech  sectors. 
They are centrally assessed by the European Agency for the Evaluation of Medicinal Products 
(EMEA),  and  covered  by  legislations  such  as  the  pharmaceutical  legislation,  which  has 
recently  undergone  a  major  review,  or  the  Orphan  Drug  Regulation.  As  a  result, 
biopharmaceuticals account today for about 20% of all marketed medicines and for over 50% 
of all medicines in the pipeline
3. Up to November 2003, twelve orphan drugs have obtained 
                                                 
3  Commission communication – “A stronger based pharmaceutical industry for the benefit of the patients 
– A call for action”  
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EU  approval.  However,  in  this  field  too,  Europe  keeps  lagging  behind  the  US
4,  and 
applications for biotech medicinal products at the EMEA have kept decreasing since 2001
5. 
To reap the benefits of biotechnology, Europe must not only address public health challenges
6 
and seize economic opportunities; it must above all show coherence and continuity in policy 
through an enabling regulatory environment and consideration for both the European and the 
global  regulatory  scene.  Healthcare  biotech  has  a  20  year  life-cycle  of  innovation  and 
investment. Therefore, incomplete and cumbersome legislation, lack of implementation or 
frequent  changes  in  Member  State  policy  will  undermine  investment  which  requires  a 
predictable  environment,  particularly  in  relation  to  intellectual  property  rights  and  timely 
market  authorisation.  Marketing  delays  not  only  create  financial  problems  for  the  SMEs 
themselves but, as importantly, they also delay patient access to innovative medicine. 
EU  assessment  and  approval  should  be  adapted  to  facilitate  global  development 
programs  for  biotech  products,  recognising  the  highly  specific  scientific  and  technical 
nature of these products. Likewise, it should take account of the specificity of the companies 
(SMEs in particular) that are sponsoring them. 
Recommendation 
CBAG calls for an adaptation of the regulatory framework according to: 
•  Scientific  and  technological  advances;  e.g.  through  a  CPMP/industry  joint 
working  group  to  develop  guidance  on  criteria  for  new  biomarkers/surrogate 
clinical end-points which could streamline and accelerate product development. 
•  Novel  biotechnology-based  healthcare  applications  that  do  not  fit  existing 
definitions; e.g. through a separate marketing authorization legislation for human 
cell and tissue based products that are neither medicines nor devices. 
•  The specificity of SMEs e.g. through specific regulatory support measures and 
adaptation of EMEA fees for SMEs. 
Because of the scientific and technical nature of biological medicinal products, companies 
developing them need a continuous dialogue with the EMEA to obtain timely and relevant 
scientific advice and to get appropriate protocol assistance.  
Recommendation 
The CBAG call for an enhanced communication and expertise: 
•  The  EMEA  should  keep  a  standing  communication  with  the  FDA  to  avoid 
assessment discrepancies between both systems. 
•  Because of the technical nature of biological medicinal products, internationally 
recognized scientific and medical experts from industry and academia should be 
                                                 
4  The  US  has  three  times  more  revenues  and  public  companies,  ten  times  the  amount  of  market 
capitalisation, twice the number of jobs even though the US has almost 30% less biotech companies. 
And the US spends almost three times as much as the EU on healthcare biotech R & D – Source: Ernst 
& Young (2002) 
5  The number of applications at the EMEA, by biotech medicinal products or active substances, dropped 
by ca. 40% between 2001 and 2002 with the exception of orphan medicines. Source: EMEA annual 
report 2002  
6  Most of biotech medicines in the pipeline are focusing on treating cancer (ca. 40%) - Source: PhRMA 
Survey (2002)  
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even  more  involved  in  the  review  process,  from  scientific  advice  down  to 
application procedure, and in the preparation of EU regulatory documents and 
guidelines.  
•  EMEA  expertise  should  be  extended  so  as  to  make  the  agency  capable  of 
assessing and authorising non-medicinal human cell and tissue-based products. 
Appropriate and consistent intellectual property protection of registration data are needed to 
ensure continued investment and innovation to meet the needs of patients and society. 
Recommendation 
•  The  CBAG  calls  for  the  maintenance  of  the  centralized  procedure  which  is 
necessary  to  ensure  a  uniform  treatment  of  biological  medicinal  products  in 
Europe, including biosimilars. 
•  To  ensure  patient  safety,  biosimilars  should  be  clearly  differentiated  from 
conventional generics, and appropriate pre-clinical and clinical data requirements 
put in place. 
Finally, European Member States must work on a system for equitable and timely access to 
medicines after EU approval. Access and reimbursement is important for patients, and are a 
key condition for SMEs to attract capital and funding.  
Recommendation 
•  The  CBAG  calls  for  the  authorisation  process  to  remain  based  on  scientific 
assessment  only  (quality,  safety  and  efficacy),  without  any  economic 
considerations, so that faster access to medicines can be achieved.  
•  The  CBAG  calls  for  unambiguous  and  explicit  reference  in  pharmaceutical 
legislation to therapies for severe unmet medical needs and for which fast track 
and exceptional circumstances provisions will grant faster patient access. In this 
regard, Member States should avail themselves of electronic patient information 
technology, to remain informed on the unmet medical needs of European citizens. 
2.  Agriculture and Food Biotechnology 
European agri-food biotechnology, both in academia and in industry, is lagging behind the 
US,  Canada,  Argentina,  Brazil  and  other  parts  of  the  world
7  in  the  use  of  modern 
biotechnology-derived crop plants, offering both socioeconomic and environmental benefits. 
The reasons for this include a European population of which the majority is wary of the use of 
genetic modification in agriculture. Another reason is the failure of the EU to have in place a 
sound science based regulatory procedure for GMOs that is enabling, rather than disabling; 
non-discriminatory,  rather  than  discriminatory;  consistent,  rather  than  inconsistent  in  its 
application, and transparent, rather than opaque in its implementation. 
Applying the EU Legislation 
The EU has a completed set of interlinked GM legislation that should be fully operational by 
mid April 2004, with the Deliberate Release Directive 2001/18/EC, the GM Food and Feed 
Regulation  (EC)  1829/2003  and  the  GM  Traceability  and  Labelling  Regulation  (EC) 
                                                 
7  See ISAAA brief 29/2003 “GLOBAL REVIEW OF Commercialized Transgenic Crops: 2002”  
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1830/2003. This set of legislation achieves two major objectives: (a) a thorough safety based 
assessment of all GMOs on a case by case basis prior to approval for cultivation, for use as 
human food and for use as animal feed; and (b) so as to provide consumers with choice, 
traceability and labelling requirements for all GMOs and food or feed derived from them, 
irrespective  of  whether  they  contain  novel  DNA  or  protein  or  whether  in  fact  they  are 
identical in every way to their non-GM counterparts. 
Recommendation 
For the CBAG, 
•  EU Member States must now implement this legislation in an enabling, 
non-discriminatory, consistent and transparent way. 
•  the Commission, as the guardian of the Treaty, has a key role to play in 
ensuring that the legislation is: 
•  properly transposed into MS National law. 
•  properly and consistently enforced in a timely manner. 
•  products assessed as safe by the scientific committees must be approved 
so that they may be offered to the market. 
•  the  large  backlog  of  submissions  resulting  from  5  years  of  a  de  facto 
moratorium on approvals must be dealt with quickly so as not to further 
distort  the  trade  difficulties  already  experienced  with  other  agricultural 
trading nations. 
•  prohibitions by Member States on already approved specific GMOs, made 
purportedly because of “new” information indicating possibility of risk, 
must, where the Scientific Committees have indicated that there is no new 
information relating to risk, be immediately withdrawn.  
Coexistence of GM crops with conventional and organic agriculture 
Directive 2001/18/EC, under Article 95 of the Treaty, sets in place the EU procedure for 
safety assessment and approval of GM products prior to their being placed on the market. A 
key “choice-permitting” component of regulation ((EC)1829/2003 and (EC) 1830/2003) was 
to  set  a  threshold  of  0.9%  above  which  GM  material,  adventitiously  present  in  non-GM 
produce, would require GM labelling. This fixed threshold is a key concept in the provision of 
choice,  and  consequently  in  the  Commission’s  Guidelines  on  Coexistence  (COM 
2003/556/EC). 
Recommendation 
For the CBAG, 
•  the  Commission  must  ensure  that  Article  95  of  the  Treaty,  under  which 
2001/18/EC  operates,  is  applied  so  that  EU  approved  products  are  not 
arbitrarily prohibited by National or Regional law from being offered to the 
market in certain Member States or Regions of Member States.  
•  it  is  crucial  that  the  Commission  follow  through  with  obligations  on  the 
coexistence  of  the  different  farming  methods.  In  working  to  establish 
guidelines for coexistence, the institutions must recognise the 0.9% labelling 
threshold as the guiding baseline in establishing coexistence. 
•  those wishing to offer produce guaranteed to be lower than this legally binding 
threshold must themselves be responsible for the additional measures required  
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to achieve their chosen threshold. 
Seed – adventitious presence of GM in non-GM seed 
For the past four years, the European seed industry has operated in an environment without 
consistent EU approach of adventitious presence of GM seed in non-GM seed. It has operated 
in a business environment without legal certainty and in which different Member States have 
managed the issue in very disparate ways. The failure to act on this crucial issue over the past 
four  years  has  resulted  in  chaos  for  the  conventional  non-GM  seed  industry  across  the 
different Member States. 
Recommendation 
The CBAG requests: 
•  legal certainty for the seed industry and, in particular, the urgent completion 
by the Commission of legislation that sets in place practicable thresholds for 
the adventitious presence of EU approved GM seed in non-GM seed. 
3.  Industrial and Environmental Biotechnology 
Europe is still a frontrunner in Industrial Biotechnology (IB) research and innovation, a key 
technology  to  make  industrial  production  more  sustainable  environmentally  and 
economically. But its global competitive position is eroding quickly, due to the long term 
strategic investments in the new technology by the United States and East Asia, as well as to 
Europe’s  structural  weaknesses.  Europe’s  academic  research  and  industry  suffer  from 
fragmentation and from a lack of incentives for innovation in sustainable industrial production 
and for its adoption by companies. 
Recommendation 
To keep its competitive position, the CBAG asks Europe to 
•  create  a  common  platform  to  overcome  fragmentation  of  research  and 
innovation in Europe, 
•  enhance  co-operation  between  academy  and  industry  in  public-private 
partnerships, 
•  develop  a  common  vision,  political  strategy  and  action  plan  with  the 
relevant stakeholders. 
Sustainable  industrial  production  and  consumption  is  one  of  the  focus  areas  of  the 
Gothenburg  summit  strategy  for  a  more  sustainable  Europe  and  of  the  Environmental 
Technologies Action Plan (ETAP). Industrial Biotechnology will contribute significantly to 
reduce  the  environmental  footprint  in  a  number  of  industry  sectors,  like  chemicals, 
pharmaceuticals or textiles. However, policy makers, entrepreneurs and the general public 
lack awareness about Industrial Biotechnology’s potential to enhance sustainable industrial 
production by reducing energy and raw material use, waste, as well as costs.  
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Recommendation 
To enhance industrial sustainability, the CBAG asks Europe to: 
•  encourage the use of industrial biotechnological processes for improving 
environmental and economic sustainability, 
•  develop incentives to facilitate adoption of these processes by industry, 
•  support the use of renewable materials for bio-materials that are more 
eco-efficient than comparable non-renewable materials, 
•  reduce  biological  feedstock  prices,  needed  to  enhance  biological 
production,  by  taking  appropriate  legislative  measures  and  furthering 
research in more efficient forms of biomass conversion. 
Concerning  the  food  enzyme  legislation  under  preparation  (draft  proposal  WGA/003/03), 
industry expects a clear and simple approval system, while keeping the present definitions of 
processing  aids  based  on  “non-functionality”  in  the  final  food.  Industry  also  needs 
clarification of the scope of the GM-Food/Feed regulation as to products produced with GM 
microorganisms no longer present in the final product, as well as clear Commission guidance 
as to whether to consider self-cloned organisms as GMOs when implementing Regulation 
90/219. 
Recommendations 
The CBAG calls for  
•  introduction of a transparent approval system, 
•  clarification of the scope of regulation on GM Food/Feed concerning 
GM microorganisms no longer present in the final product, 
•  a  clear  implementation  guide  from  the  Commission  on  regulation 
90/219 considering self-cloned organisms as GMOs. 
 